


GLAXOSMITHKLINE CONTRACT EXTENSION

Oncology Associates is pleased to announce a contract extension for GlaxoSmithKline. Products on contract include: Arixtra, Hycamtin and Zofran Injection 20 ml vials and 32 mg premixed bags. The extension will run until December 31, 2006. To discuss any questions about the GlaxoSmithKline agreement, please contact OA at **888-732-7352**.




IN OTHER NEWS...

NANOPARTICLE ALBUMIN–BOUND PACLITAXEL FOR METASTATIC BREAST CANCER

The taxanes, paclitaxel and docetaxel, are among the most important drugs in the modern treatment of metastatic breast cancer. By the mid 1990s, several phase II trials had demonstrated both agents to have considerable activity in the metastatic setting.¹⁻⁵ Phase III trials were then conducted to compare these agents with the then reference agent, doxorubicin.

To view this article in its entirety from VOLUME 23 NUMBER 31 NOVEMBER 1, 2005 of the Journal of Clinical Oncology, visit the OA website at www.oagpo.com. The link is on the homepage under News and Events.


NEW J-CODE FOR ABRAXANE

 Abraxis has been issued a unique HCPCS code, **J-9264, 1 mg** (Injection, Paclitaxel Protein-Bound Particles).

J9264 is effective for dates of service on or after **January 1, 2006** and will be used to bill all payers (Medicare, Medicaid and commercial/private plans).

Reimbursement assistance is available through the ARC of Support Hotline. Reimbursement Counselors are waiting to help you Monday through Friday from 8:00am – 8:00pm ET, **1-800-564-0216, Option 3**.

NEW J-CODE FOR VIDAZA

 The Centers for Medicare and Medicaid Services (CMS) has established a HCPCS Level II code for Vidaza. The product specific "J"-code assigned to Vidaza is **J9025, "INJECTION, AZACITIDINE, 1 MG."** The effective date for use of J9025 is **January 1, 2006**.

For assistance with your reimbursement questions contact the Vidaza Reimbursement Hotline at **1-866-PHARMION**.

